Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Geun Joo | - |
dc.contributor.author | Kim, Hyun Min | - |
dc.contributor.author | Kang, Hyun | - |
dc.contributor.author | Kim, Jaetaek | - |
dc.date.available | 2019-03-08T15:58:01Z | - |
dc.date.issued | 2016-07-02 | - |
dc.identifier.issn | 0300-7995 | - |
dc.identifier.issn | 1473-4877 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/8697 | - |
dc.description.abstract | Objectives: Several meta-analyses have confirmed the positive metabolic effects of telmisartan, an angiotensin II receptor blocker that can also act as a partial peroxisome proliferator-activated receptor-gamma agonist, compared to those of other angiotensin II receptor blockers. These effects include decreased fasting glucose, glycosylated hemoglobin, interleukin-6, and tumor necrosis factor-alpha levels. However, no systemic analysis of telmisartan's effects on body fat distribution has been performed. We performed a meta-analysis of randomized controlled telmisartan trials to investigate its effects on body weight, fat distribution, and visceral adipose reduction. Research design and methods: A literature search was performed using Embase, MEDLINE, and the Cochrane Library between January 1966 and November 2013. Randomized controlled trials in English and meeting the following criterion were included: random assignment of hypertensive participants with overweight/obesity, metabolic syndrome, or glucose intolerance to telmisartan or control therapy group. Results: Of 651 potentially relevant reports, 15 satisfied the inclusion criterion. While visceral fat area was significantly lower in the telmisartan group than in the control group (weighted mean difference = -18.13cm(2), 95% C.I. = -27.16 to -9.11, P-X(2) = 0.19, I-2 = 41%), subcutaneous fat area was similar (weighted mean difference = 2.94 cm(2), 95% C.I. = -13.01 to 18.89, P-X(2) = 0.30, I-2 = 17%). Total cholesterol levels were significantly different between the groups (standardized mean difference = -0.24, 95% C.I. = -0.45 to -0.03, P-X(2) = 0.0002, I-2 = 67%). Limitations: Limitations include: (1) limited number of studies, especially those evaluating fat distribution; (2) different imaging modalities to assess visceral fat area (V.F.A.) and subcutaneous fat area (S.F.A.); (3) observed heterogeneity. Conclusion: The findings suggest that telmisartan affected fat distribution, inducing visceral fat reduction, and thus could be useful in hypertensive patients with obesity/overweight, metabolic syndrome, or glucose intolerance. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.identifier.doi | 10.1185/03007995.2016.1171204 | - |
dc.identifier.bibliographicCitation | CURRENT MEDICAL RESEARCH AND OPINION, v.32, no.7, pp 1303 - 1309 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000378329800016 | - |
dc.identifier.scopusid | 2-s2.0-84963799625 | - |
dc.citation.endPage | 1309 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1303 | - |
dc.citation.title | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.citation.volume | 32 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Body fat distribution | - |
dc.subject.keywordAuthor | Hypertension | - |
dc.subject.keywordAuthor | Obesity | - |
dc.subject.keywordAuthor | Telmisartan | - |
dc.subject.keywordPlus | ADIPOSE-TISSUE DISTRIBUTION | - |
dc.subject.keywordPlus | ACTIVATED RECEPTOR-DELTA | - |
dc.subject.keywordPlus | TYPE-2 DIABETIC-PATIENTS | - |
dc.subject.keywordPlus | TO-HEAD TRIALS | - |
dc.subject.keywordPlus | IMPROVES INSULIN-RESISTANCE | - |
dc.subject.keywordPlus | IMPAIRED FASTING GLUCOSE | - |
dc.subject.keywordPlus | BLOOD-PRESSURE CONTROL | - |
dc.subject.keywordPlus | NECROSIS-FACTOR-ALPHA | - |
dc.subject.keywordPlus | ALL-CAUSE MORTALITY | - |
dc.subject.keywordPlus | HYPERTENSIVE PATIENTS | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.